Cerebras Upsized IPO

In a normal IPO, bookbuilding is a slow tide: underwriters set an initial price range, road-show the deal for two weeks, gauge institutional interest, and price near the midpoint on listing eve. Cerebras has done something different. The original terms — 28 million shares at $115-$125 — would have raised roughly $3.5 billion <research_source_url_1>. Within days, indications of interest from institutions exceeded the available float by more than 20 times <research_source_url_2>. That kind of cover ratio is what underwriters call a 'multiple-times-oversubscribed' book; when it crosses 10x it typically triggers an upsize, and when it crosses 20x it forces a meaningful repricing because allocators are signaling they would accept a materially higher clearing price. Joint book-runners Morgan Stanley, Citigroup, Barclays, and UBS responded by lifting the range to $150-$160 on 30 million shares, raising the targeted proceeds to approximately $4.8 billion <research_source_url_3> <research_source_url_1>.

What 20x oversubscription actually means in practice is that for every share offered, more than twenty shares' worth of orders were submitted at or above the indicated price. That does not mean every order is firm at the new top of range — some orders are conditional, some get cut on allocation — but it does mean the bankers have very high confidence the deal will clear at $160 and that aftermarket appetite is real. The flip side, and the reason sophisticated investors are paying attention to the cadence, is that lifting both the share count and the price range in such a compressed window is unusual. It suggests either that the original range was deliberately conservative to manufacture momentum, or that the demand environment is moving so fast that underwriters are repricing in near-real time. Either reading carries implications for how the stock trades when CBRS is expected to list on Nasdaq <research_source_url_4>.

Customer concentration is a standard S-1 risk factor. Cerebras's relationship with OpenAI is something more structural. OpenAI is, simultaneously, Cerebras's anchor customer (a 750-megawatt multi-year compute commitment valued at over $20 billion), a lender ($1 billion extended at 6% to fund data center buildout), and a warrant holder (over 33 million Class N shares) <research_source_url_5> <research_source_url_4>. In equity terms, Cerebras's largest customer is also among its largest economic claimants on the upside. That is a structure usually associated with strategic joint ventures, not arms-length supplier contracts.

The bull case is straightforward: a $20B-plus multi-year commitment provides revenue visibility most IPO chipmakers can only dream of, and it converts what would be a speculative inference bet into a contracted backlog. The bear case is equally clean. Cerebras's S-1 disclosures show that G42 accounted for 24% of 2025 revenue (down from 85% in 2024) and MBZUAI alone made up 62% of 2025 revenue <research_source_url_5>. Layering OpenAI on top concentrates the customer base even further. If OpenAI's own compute mix shifts — toward its in-house silicon ambitions, toward more diversified inference partners, or simply through renegotiation — Cerebras's revenue trajectory does not have many places to hide. The warrants make the picture more interesting still: as Cerebras's equity value rises, OpenAI's economic interest as a warrant holder grows alongside it, meaning OpenAI has direct upside exposure to the very stock its purchasing decisions support. This is the entanglement skeptics are pricing, even as institutional buyers treat it as a feature rather than a bug.

The most striking feature of the community conversation is not that retail investors are skeptical — they often are around hot AI listings — but where the skepticism is and isn't. Retail discussion on r/stocks is sharply split, with the most upvoted analytical post arguing that at $160 Cerebras trades at roughly PS 67x on a 43% gross margin with three major customers, a profile that compares unfavorably to Nvidia, Broadcom, and AMD on essentially every axis the writer considered. The conclusion that gained the most traction was blunt: the bankers have repeatedly repriced the deal beyond what the underlying fundamentals would support on a comparable-multiples basis. A separate widely-upvoted thread surfaced a more tactical view: with small-float AI IPOs, the relevant inflection point is often the six-month lock-up expiry, when pre-IPO holders unlock and can compress price toward fundamentals.

What is notably absent from the skeptical case is any serious dispute about the technology. The WSE-3 wafer-scale engine is, by independent equity-research accounts, roughly 57 times larger than the largest competing GPU die and delivers inference throughput in the range of 1,800-2,100 tokens per second versus approximately 90-150 on Nvidia's H100 <research_source_url_6>. Even Reddit's most cited bear acknowledges those numbers. The disagreement is entirely about the entry price relative to defensible margin structure, customer concentration, and Nvidia's CUDA-driven switching costs, which independent analysts describe as 'measured in years' <research_source_url_6>. In other words, the institutional bid and the sophisticated retail skeptic are looking at the same chip and reaching opposite conclusions about valuation — a rare and clean disagreement that the first weeks of CBRS trading will help arbitrate.

The most underappreciated context for today's pricing is how recently Cerebras was valued at a small fraction of where it is about to list. Cerebras filed its first S-1 in September 2024 <research_source_url_7>. That offering was effectively frozen by a CFIUS review of the company's ties to Abu Dhabi's G42, which at the time accounted for 85% of Cerebras's revenue <research_source_url_5>. CFIUS cleared the review in March 2025, but by then the deal calendar had moved on. In October 2025, Cerebras formally withdrew its registration and raised a $1.1 billion private round at an $8.1 billion valuation <research_source_url_7>. That price tag — set by sophisticated late-stage private investors with full access to financials — was the company's reference point seven months ago.

At the top of the current range, Cerebras would list at a fully diluted valuation of roughly $48.8 billion <research_source_url_3>. That is approximately a 6x markup from the October 2025 private round, in a span of about seven months. Some of that markup is genuinely earned: 2025 revenue grew 76% to $510 million, net income reached $238 million (a 47% net margin), and the OpenAI compute commitment materially de-risked future revenue <research_source_url_5> <research_source_url_6>. Some of it is the demand environment: the global AI inference market is estimated at $106.2 billion in 2025 and projected at $255 billion by 2030 <research_source_url_8>, and CBRS is a relatively rare pure-play. But the steepness of the re-rating — combined with repeated upward revisions to both share count and price range in a single week — is itself the central narrative of this offering. Cerebras is not just going public; it is going public at a price that requires the inference thesis to substantially deliver.